4D Molecular Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for FDMT, updated each market day.
FDMT AI Sentiment
AI sees no strong directional signal for 4D Molecular Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About 4D Molecular Therapeutics, Inc. Common Stock
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Sector
Exchange
Market Cap
$810,985,017
Cap Tier
Employees
196
Headquarters
EMERYVILLE, CA
Listed Since
Dec. 11, 2020
FDMT Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
FDMT Volatility
4D Molecular Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
